This Monday, December 26, the administration of the supplemental booster vaccine against
COVID-19
for people over 80 or immunocompromised in Montevideo. Application for these same groups of people but from within will begin on Monday 2 January.
The MSP has indicated that the inoculation will be performed no agenda. The availability of the vaccine only for certain sections of the population takes place because it will happen gradually. The portfolio assured that “the dates on which the administration of the complementary dose of reinforcement will begin in the other groups will be promptly communicated”.
“In all cases, you must wait 180 days after the last dose of covid-19 vaccine received, the same after making the disease”, indicated the wallet. The ministry also recommended “above all that the people over the age of 50 the third and fourth doses are administered as appropriate”.
The MSP began this new vaccination campaign after several weeks of sustained growth in the number of infections and hospitalizations. In the last week the cases increased by 87% compared to previous weeks.
The MSP has posted a list of the
Vaccinations authorized for people over 12 years of age
and the
authorized pediatric vaccination
.
Causes of immunosuppression:
- Chemotherapy and active radiotherapy for solid tumors and haematological malignancies.
- Solid organ or hematopoietic progenitor transplant recipients.
- Moderate or severe primary immunodeficiency (for example, common variable immunodeficiency disease, severe combined immunodeficiency, among others).
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts below 200/mm3, without antiretroviral therapy).
- Chronic patients on dialysis.
-
Patients with autoimmune diseases treated with immunosuppressants (see list):
– High doses of corticosteroids (i.e. 20 or more mg of prednisone or its equivalent per day when given for 2 or more weeks).– Biological
- Monoclonal antibodies such as anti-TNF, such as infliximab, tocilizumab, adalimumab, certolizumab, etanercept, golimumab. In case of anti-CD20 such as Rituximab (up to 6 months after the last treatment)
- Janus Kinase (JAK) Inhibitors Tofacitinib, Upadacitinib,
- Bruton’s tyrosine kinase inhibitors (ibrutinib)
- Methotrexate
- Azathioprine
- 6-mercaptopurine
- Cyclophosphamide
- Leflunomide
- Interferons
- Mycophenolate mofetil
- Calcineurin inhibitors (tacrolimus, cyclosporine)
- Sulfazalazine
- fingolimod
- Complement inhibitors: Eculizumab
- Other drugs not included in the list that are associated with immunosuppression at the discretion of the treating physician.
